Biomarker hub
HER2 / ERBB2
Trials and papers mentioning HER2 / ERBB2.
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
ACTIVE_NOT_RECRUITING · Phase not listed
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
RECRUITING · Phase not listed
Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer
NOT_YET_RECRUITING · Phase not listed
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
ACTIVE_NOT_RECRUITING · Phase not listed
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
RECRUITING · Phase not listed
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
RECRUITING · Phase not listed
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
ACTIVE_NOT_RECRUITING · Phase not listed
Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
RECRUITING · Phase not listed
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
RECRUITING · Phase not listed
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase not listed
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase not listed
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RECRUITING · Phase not listed
A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors
COMPLETED · Phase not listed
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
RECRUITING · Phase not listed
Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.
RECRUITING · Phase not listed
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
RECRUITING · Phase not listed
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RECRUITING · Phase not listed
FTT PET/CT in Pancreatic Neuroendocrine Tumors
RECRUITING · Phase not listed
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
RECRUITING · Phase not listed
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase not listed
CDK4/6 inhibition provides additional efficacy in HER2 + , HR + breast cancer.
Nature reviews. Clinical oncology · 2/17/2026
CDK4/6 inhibitors combined with fulvestrant for the treatment of HR+/HER2-advanced or metastatic breast cancer: a Bayesian network meta-analysis.
BMC cancer · 2/17/2026
Recurrent ERBB2 alterations are associated with esophageal adenocarcinoma brain metastases
genetic and genomic medicine · 2/26/2025